Medtronic revises labeling for spinal cord stimulation device

The FDA approved revised commercial labeling for Medtronic's Intellis Platform with Differential Target Multiplexed programming.

The new labeling will include outcomes from a study showing "superior back pain relief" compared to conventional spinal cord stimulation, according to a March 17 news release.

Eighty-four percent of patients in the 12-month randomized controlled study reported at least 50 percent pain relief after being treated with the DTM system. Fifty-one percent of patients reported the same pain relief using a conventional spinal cord stimulator.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast